Treating and Reducing Risk of Developing Alzheimer's Disease with AAV-mediated CRISPR/Cas9 Engineering of the TREM2 Gene in Microglia

About The Project

Alzheimer's Disease is a neurodegenerative disorder characterized by the progressive loss of memory, judgement, and the ability to function. It is linked to desposits of amyloid-beta peptides that damage neural synapses. Microglia, the immune cells of the brain, are activated to clear these deposits, but are often overactivated and cause neuroinflammation. I propose editing the TREM2 gene, which regulates inflammation and phagocytosis, in microglia using CRISPR/Cas9 engineering systems delivered with adeno-associated viruses (AAVs), reducing the inflammatory effects of microglia, permitting safe beta-amyloid clearance.